Sector News

Flailing Wilex finds a lifeline as Roche steps in with an ADC deal

October 14, 2014
Life sciences
Germany’s Wilex has long been on the way out of biotech, but a new collaboration with Roche provides the company with some cash up front and a shot at down-the-line royalties.
 
Under the deal, Roche has agreed to pay as much as €52 million ($65.8 million) for the exclusive rights to an undisclosed tumor target. Roche also extended its relationship with Heidelberg Pharma, Wilex’s CRO subsidiary that out-licenses the biotech’s proprietary antibody-drug conjugate technology.
 
Wilex didn’t say how much of the sum comes in the form of up-front cash, but, for a company that has spent the past year struggling to keep the doors open, any income is a positive.
 
The Munich company’s problems began in 2012, when Rencarex, a renal cell carcinoma treatment, failed a Phase III trial. After a year of “intensive efforts” to find investors, Wilex let go of 80% of its staff in January and unveiled plans to gradually exit all clinical development, transitioning into a service provider.
 
So far, the company has signed over the Chinese rights to the Phase II pancreatic and breast cancer treatment Mesupron in a €7 million ($9.6 million) deal with Link Health, trading rest-of-the-world ownership of the drug to Israel’s RedHill Biopharma for $1 million up front and future royalties. And, in May, Wilex handed back 5 once-promising cancer treatments to ex-partner UCB in exchange for cancellation fees and some debt forgiveness.
 
Wilex co-founder and CEO Olaf Wilhelm stepped down in March after about 17 years with the company, replaced by CFO Jan Schmidt-Brand. The company, a Fierce 15 honoree back in 2005, was originally launched with the help of German billionaire Dietmar Hopp.
 
By Damian Garde
 
 

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach